| | 1202757-89-8 Basic information More.. |
| Product Name: | AVL-292 | | Synonyms: | AVL-292;LMK-435;N-[3-[[5-Fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-2-propenamide;2-Propenamide, N-[3-[[5-fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-;CC-292 (AVL-292);CC-292,LMK-435;N-[3-[[5-Fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-2-propenamide AVL292;CC-292 | | CAS: | 1202757-89-8 | | MF: | C22H22FN5O3 | | MW: | 423.44 | | EINECS: | | | Mol File: | 1202757-89-8.mol |  |
Use
Bruton’s tyrosine kinase (BTK) is a non-receptor tyrosine kinase involved in signal transduction pathways regulating the proliferation, activation, and differentiation of B cells. AVL-292 is an orally available, selective, and irreversible inhibitor of BTK (IC50 = 0.5 nM in vitro in B cell lymphoma cell lines) that targets and covalently binds to BTK at cysteine-481, thereby preventing its activity. AVL-292 has been shown to inhibit osteoclast function and to reduce osteoclast-stimulated proliferation of multiple myeloma cells in animal models of rheumatoid arthritis and multiple sclerosis, both of which are diseases where B cells play an important role. In clinical trials, AVL-292 has demonstrated therapeutic significance in the treatment of both B cell-related cancers (e.g., non-Hodgkin’s lymphoma and B cell chronic lymphocytic leukemia) and autoimmune diseases (e.g., rheumatoid arthritis).[Cayman Chemical]
- AVL-292
-
- US $0.00 / gram
- 2022-02-18
- CAS:1202757-89-8
- Min. Order: 1gram
- Purity: 99%
- Supply Ability: 10kg
- AVL-292
-
- US $2.00 / kg
- 2019-07-06
- CAS:1202757-89-8
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100kg
|
|
1202757-89-8
Recommend Suppliers |
|